Robert E. Landry - 21 Mar 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role: EVP Finance CFO
Signature: /s/**Robert E. Landry
Issuer symbol: REGN
Transactions as of: 21 Mar 2022
Net transactions value: -$270,821
Form type: 4
Filing time: 23 Mar 2022, 16:02:51 UTC
Previous filing: 18 Mar 2022
Next filing: 30 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	REGN	Common Stock	Sale	$207,900	-300	-1%	$693.00	28,656	21 Mar 2022	Direct	F1
transaction	REGN	Common Stock	Options Exercise	$152,768	+400	+1.4%	$381.92	29,056	21 Mar 2022	Direct
transaction	REGN	Common Stock	Tax liability	$215,689	-312	-1.1%	$691.31	28,744	21 Mar 2022	Direct
holding	REGN	Common Stock						229	21 Mar 2022	By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	REGN	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-400	-2.1%	$0.000000	18,800	21 Mar 2022	Common Stock	400	$381.92	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2	The stock option award vests in four equal annual installments, commencing one year after the date of grant.